pag. 60 BIBLIOGRAFIA
1. Diabetes and Impaired Glucose Tolerance. Global Burden:
Prevalence and Projections, 2010 and 2030. Sito Web International Diabetes Federation Diabetes Atlas.
(http://www.diabetesatlas.org/content/diabetesand-impaired-glucose-tolerance)
2. Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the US. Diabetes Care 2009; 32: 2225-2229.
3. Standards of medical care in diabetes - 2010. Association, American Diabetes. 33, 2010, Diabetes Care, p. (Suppl.1) S11-61.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
5. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68: 2131–2162.
6. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008;
34 Suppl 2: S65–S72.
pag. 61 7. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122: S3–S10.
8. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C- peptide responses. J Clin Endocrinol Metab 1986; 63: 492–498.
9. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolysis gastric inhibitory polypeptide, glucagon-like peptide 1 (7- 36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
10. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828.
11. Brown JC, Dryburgh JR, Ross SA, and Dupre´ J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 1975; 31: 487–532.
12. Mayo KE, Miller LJ, Bataille D et al. International Union of Pharmacology, XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167-194.
13. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
pag. 62 14. Lynn FC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabeticfatty Zucker rats. Diabetes 2001; 50: 1004–1011.
15. Bell GI, Santerre RF, and Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716–718.
16. Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.
Endocrinology 1986; 119: 1467–1475.
17. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)- amide.
Diabetes 1989; 38. 902–905.
18. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81. 327–332.
19. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397–4408.
pag. 63 20. Vilsbøll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609–613.
21. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Lancet 2009; 374: 39–47.
22. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
Diabetologia 1986; 29: 46-52.
23. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;
36(8): 741-744.
24. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;
30, 358(3): 219-224.
25. Körner M, Stöckli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48(5): 736-743.
pag. 64 26. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144(12): 5149-5158.
27. Brun T, He KH, R, et al. The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1. Hum Mol Genet 2008; 15, 17(4): 478-789.
28. Xu G, Kaneto H, Lopez-Avalos MD, et al. GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts.
Diabetes Res Clin Pract 2006; 73(1): 107-110.
29. Creutzfeld WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36)amide in type 1 diabetic patients. Diabetes Care 1996; 19: 580-586.
30. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-410.
31. Read N, French S, Cunningham K. The role of the gut in regulation food intake in man. Nutr Rev 1994; 52: 1-10.
32. Tang-Christensen M, Larsen PJ, Thulesen J, et al. The proglucagon-derived peptide, glucagon-like peptide-2, is a
pag. 65 neurotrasmettitor involved in the regulation of food intake. Nat Med 2000; 6: 802-807.
33. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide 1(7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
34. Henry RR, Ratner RE, Stonehouse AH, et al. Exenatide maintained glycemic control with associated weight loss reduction over 2 years in patients with type 2 diabetes. Diabetes 2006; 55:
A116.
35. Larsen PJ, Holst JJ. Glucagon-related peptide 1: hormone and neurotransmitter. Regul Pept 2005; 128: 97-107.
36. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide 1 receptor is involved in learning and neuroprotection. Nat Med 2003;
9: 1173-1179.
37. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide 1 receptor. Endocrinology 2003; 144: 2242- 2252.
38. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-478.
pag. 66 39. Ayala JE, Bracy DP, James FD, et al. The GLP-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009; 150: 1155- 1164.
40. Crowley VE, Yeo GS, O'Rahilly S. Obesity theraphy: Altering the energy intake and expenditure balance sheet. Nat Rev Drug Disc 2002; 1: 276.
41. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402–7405.
42. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exanetide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
43. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90(11): 5991-5997.
pag. 67 44. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-1100.
45. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2628-2635.
46. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opinion 2008; 24(1): 275-286.
47. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a oncedaily human GLP-1 analogue, improves pancreatic B-cell function and arginine- stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25(2): 152-156.
48. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284(6): E1072-1079.
49. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 8, 335(7631): 1194-9.
pag. 68 50. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double- blind, placebo-controlled trials. Clin Ther 2007; 29(1): 139-153.
51. Mari A, Nielsen LL, Nanayakkara N, et al. Mathematical modeling shows exenatide improbe beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Horm Metab Res 2006; 38(12): 838-844.
52. UKPDS Study group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet 1998; 352(9131): 837-853.
53. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8(4): 436-447.
54. Stefan N, Kantartzis K, Haring HU. Causes and metabolic conseguences of fatty liver. Endocr Rev 2008; 29(7): 939-960.
pag. 69 55. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipid production in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288 :G943-G949.
56. Harder H, Nielsen L, Tu DT, Astrup A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915-1921.
57. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30: 217–223.
58. Horton ES, Silberman C, Davis KL, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010; 33: 1759–1765.
59. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
JAMA 2007; 11, 298(2): 194-206.
60. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 18, 143(8): 559-569.
pag. 70 61. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006; 29(2): 471.
